![](https://d3ilqtpdwi981i.cloudfront.net/GxuY4dJf_Ot78nJRFzO2uqHLIDM=/47x0:238x248/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/06/ef/c5/06efc50c-adb5-40fc-a963-1fc8c985b9d4/ArticleViewerPreview%402.01720610-201806000-00007.F1-7.jpeg)
Article
The role of SGLT2 inhibitors in managing Type 2 Diabetes
JAAPA
(2018)
Abstract
The sodium glucose cotransporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin represent a novel class of medications to manage type 2 diabetes through urinary excretion of glucose. These drugs block glucose reabsorption by the kidneys to increase glucosuria. These drugs provide hemoglobin A1C reduction, promote weight loss, and remain hypoglycemic-neutral when not used in combination with insulin or secretagogues. Canagliflozin and empagliflozin have shown cardiovascular benefit. The potential to reduce the risk of cardiovascular death in patients with type 2 diabetes, along with the benefit of weight reduction, makes these new agents useful tools for the primary care provider.
Keywords
- Diabetes,
- SGLT2 Inhibitors,
- Type 2 Diabetes
Disciplines
Publication Date
June, 2018
DOI
10.1097/01.JAA.0000533660.86287.04
Citation Information
Velen Tat and Christopher Forest. "The role of SGLT2 inhibitors in managing Type 2 Diabetes" JAAPA Vol. 31 Iss. 6 (2018) p. 35 - 40 Available at: http://works.bepress.com/christopher-forest/32/